For research use only
| Cat No. | ABC-X0072C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
NCOA4-RET BAF3 Cell Line serves as a functional model to study RET fusion–driven signaling and supports preclinical RET-targeted therapy development.
Human NCOA4_RET BAF3 Cell Line is a lentivirally engineered Ba/F3 cell line overexpressing the NCOA4-RET fusion gene. Cells are maintained at low passage numbers (<P20) and validated at the transcriptional level by qRT-PCR. Target The NCOA4-RET fusion results from chromosomal rearrangements and is observed in thyroid and lung cancers. It activates oncogenic RET kinase signaling, driving cell proliferation and transformation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0072C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model is widely used in mechanistic studies of RET fusion-mediated tumorigenesis and for preclinical testing of RET-specific inhibitors. It also facilitates research on resistance mechanisms and combination therapies.